Comparative performance of two automated machine learning platforms for COVID-19 detection by MALDI-TOF-MS

The 2019 novel coronavirus infectious disease (COVID-19) pandemic has resulted in an unsustainable need for diagnostic tests. Currently, molecular tests are the accepted standard for the detection of SARS-CoV-2. Mass spectrometry (MS) enhanced by machine learning (ML) has recently been postulated to...

Full description

Saved in:
Bibliographic Details
Published inPloS one Vol. 17; no. 7; p. e0263954
Main Authors Rashidi, Hooman H., Pepper, John, Howard, Taylor, Klein, Karina, May, Larissa, Albahra, Samer, Phinney, Brett, Salemi, Michelle R., Tran, Nam K.
Format Journal Article
LanguageEnglish
Published San Francisco Public Library of Science 29.07.2022
Public Library of Science (PLoS)
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The 2019 novel coronavirus infectious disease (COVID-19) pandemic has resulted in an unsustainable need for diagnostic tests. Currently, molecular tests are the accepted standard for the detection of SARS-CoV-2. Mass spectrometry (MS) enhanced by machine learning (ML) has recently been postulated to serve as a rapid, high-throughput, and low-cost alternative to molecular methods. Automated ML is a novel approach that could move mass spectrometry techniques beyond the confines of traditional laboratory settings. However, it remains unknown how different automated ML platforms perform for COVID-19 MS analysis. To this end, the goal of our study is to compare algorithms produced by two commercial automated ML platforms (Platforms A and B). Our study consisted of MS data derived from 361 subjects with molecular confirmation of COVID-19 status including SARS-CoV-2 variants. The top optimized ML model with respect to positive percent agreement (PPA) within Platforms A and B exhibited an accuracy of 94.9%, PPA of 100%, negative percent agreement (NPA) of 93%, and an accuracy of 91.8%, PPA of 100%, and NPA of 89%, respectively. These results illustrate the MS method’s robustness against SARS-CoV-2 variants and highlight similarities and differences in automated ML platforms in producing optimal predictive algorithms for a given dataset.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Competing Interests: N.T. is a consultant for Roche Diagnostics and Roche Molecular Systems. He is also a co-inventor / co-owner of MILO-ML, LLC. H.R. is also a co-inventor / co-owner of MILO-ML, LLC. J.P. is a co-founder and employee of SpectraPass, LLC. L.M. is a consultant for Roche Diagnostics and Roche Molecular Systems. S.A. is a co-inventor / co-owner of MILO-ML, LLC. T.H., K.K., B.P., and M.S. have no competing interests.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0263954